About Us

We are medics, statisticians, technologists, and medical writers purposed to develop solutions and services that can enhance evidence generation, medical writing, and statistics across all phases of drug development. Our aim is to accelerate research by providing advanced solutions using AI and Machine Learning for RWE and Epidemiology. Given the speed of development, the need for experienced and dedicated resources is important, and we provide services for Biostatistics, Programming, Medical Writing & RWE.

We are Genpro Research

Genpro brings together the global best practices in Clinical Data Management, Biostatistics, Programming, Medical Writing, and Strategic Consulting. We deliver cost-effective solutions to our clients on time with international quality.

Our Mission

Our mission is to support our clients in achieving their goals by providing knowledge driven innovative solutions with highest quality products and services.

Who We Are

Genpro Research started by technologists, biostatisticians, and clinicians to make an impact on the way we use data from all sources, to make development decisions in clinical trials. We work with you to provide a dedicated, communicative team in Biostatistics & DM/Programming, Medical Writing. And to our larger clients that require a technology partner, we come from a clinical background and understand drug development and scientific challenges. We have engineered a platform, called MaiA, that uses Machine Learning and Natural Language Processing algorithms to enable automation of several processes related to competitive intelligence and depth in understanding all literature sources related to the diverse needs of the patients, safety issues, economic evaluations assessing treatments, amongst many other areas related to drug development. Our team is based in US, EU, New Zealand, and India.

Next-generation services and technology partner for the pharmaceutical, biotechnology, and medical devices industry.

Genpro Research is a next-generation services and technology partner for the pharmaceutical, biotechnology, and medical devices industry. Our tools use Artificial Intelligence, Machine Learning, and Natural Language Processing algorithms to enable automation of several processes throughout drug development and post-launch activities. We provide advanced solutions in Biostatistics & Programming, Medical Writing, and Regulatory Submissions. Genpro has a diverse talent pool of professionals with several years of industry experience along with a young and energetic set of professionals from some of the leading institutions.

Genpro has launched MaiA, an advanced end-to-end framework that increases efficiency and mitigates the pain points of literature reviews. This platform quickly produces quality literature review summaries/ disease context summaries/ TA landscaping and Systematic Literature Reviews (SLRs) for Epidemiology, medical affairs, and medical information teams. It can reduce the cognitive workload of the writers and analysis by 50-70%. MaiA was co-developed and tested with one of the world’s top five pharma company. Genpro provides excellent work-life balance by adopting global Flexi work practices. Genpro team has been working for more than 15 years in NDA/ BLA/PMA submissions, interacting with FDA/ EMEA & PMDA, and actively collaborating with academic, industry, and FDA working groups.
0
Product Deployments
0
Total Studies
0
Clients

Executive Leadership

Anoop P Ambika

Chief Executive Officer

Kapil Khambholja Ph.D

Chief Scientific Officer

Limna Salim

Director, Biometrics

Dr. Sachin Marulkar

President & Chief Medical Officer

Shariq Alavi

Vice President of Business Development

Natasa Rajicic

Consulting Biostatistician

Vikash Jain

Head of Statistical Programming

Ramadevi Ramanathan

Manager - Compliance & Quality Assurance

Salih Siam

Senior Director, Sales & Business Development

Seema Alex

Manager - HR & Administration

Sindhu Pillai

Director - India Operations

Gheorghe Doros Ph.D

Director, Statistical Consulting

Biometrics & Strategic Consulting

Athira Sudhakar

Project Lead - Biostatistics

Akhil Vijayan

Project Lead - SAS Programming

Ajith Nair

Project Manager

Roshan Stanley

Associate Project Lead

Product Development

Sruthi Pradeep

Product Manager

Raj Kiran

Technical Architect

Praveen S

UI Architect

Scientific Advisory Board

Dr. Philip T. Lavin

PhD, FASA, FRAPS
Dr. Lavin is an internationally well-known drug developer and Biostatistician with a long history of supporting clinical trials. He was a member of the Biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics which became Aptiv Solutions before being acquired by ICON plc. Dr. Lavin has authored or co-authored 160 peer-reviewed publications in the medical and statistical literature. Dr. Lavin has been the Lead Biostatistician for 64 FDA approvals to date including 39 PMAs (16 orthopaedic, 7 cardiovascular). Dr. Lavin has continuously worked on various device projects in cardiovascular, orthopaedics, periodontal indications plus In-vitro diagnostics, and imaging. Dr. Lavin received his Ph.D. in Applied Mathematics at Brown University in 1972. He is the only person to be elected a Fellow of the American Statistical Association and the Regulatory Affairs Professional Society reflecting his many pioneering contributions to statistics, regulatory approvals, and medicine. He has been associated and working with the Genpro International team for over 10 years.

Babu Sivadasan

B.S.
Babu Sivadasan is a serial entrepreneur and executive with more than 25 years of experience in product engineering, operations, mergers and acquisitions, and corporate leadership. Mr. Sivadasan has co-founded two public companies that are Envestnet and Stamps.com and, he was also instrumental in building early-stage start-ups and large enterprise software companies. Mr. Sivadasan is an alumnus of Stanford University SEP and has a B.S in Computer Science and Engineering from the University of Kerala.

Dr. Mark Chang

PhD
Dr. Mark Chang has over 20 years of experience as a statistician and, he is the founder of AGInception for Artificial General Intelligence Research. Previously, He served as Sr. Vice President, Strategic Statistical Consulting at Veristat, Vice President of Biometrics at AMAG Pharmaceuticals and, director and scientific fellow at Millennium/Takeda Pharmaceuticals. Dr. Chang is a fellow of the American Statistical Association and an adjunct professor of Biostatistics at Boston University. He is a co-founder of the International Society for Biopharmaceutical Statistics, co-chair of the Biotechnology Industry Organization (BIO) Adaptive Design Working Group, and a member of the Multiregional Clinical Trial (MRCT) Expert Group. He has published 11 books, including Artificial Intelligence for Drug Development, Precision Medicine and Healthcare, Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials, and many more.

Dr. Sachin Marulkar

MD, MPH, MBA
Dr. Sachin Marulkar is a drug development professional with 20 years of clinical, data analytics, and biometrics work experience. He currently is the clinical lead on hematology indications. He has previously held varied roles in Harvard clinical research, Genzyme, and Sanofi, providing strategic inputs in clinical development, study designs, statistical methodology, regulatory strategy, operational planning, budget planning, and product life cycle management. Dr. Marulkar has a passion for healthcare technology which can facilitate data-driven decision-making within patient-centric healthcare organizations. He is involved in mentoring start-ups in the healthcare space. Dr. Marulkar holds MD degree, master’s in public health (Drug Epidemiology and Biostatistics) from Boston University, and an MBA from Massachusetts Institute of Technology (MIT) Sloan school of business.

Dr. Paul Azunre

PhD
Paul Azunre holds a PhD in Computer Science from MIT and has served as a Principal Investigator on several DARPA research programs. He founded Algorine Inc., a Research Lab dedicated to advancing AI/ML and identifying scenarios where they can have a significant social impact. Paul also co-founded Ghana NLP, an open source initiative focused on using NLP and Transfer Learning with Ghanaian and other low-resource languages. He also serves as Director of Research at Dun & Bradstreet, a company helping businesses manage supply chain risk and other business analytics challenges. He is the author of the recently published book ``Transfer Learning for NLP`` by Manning Publications.

Dr. Mark Chang

PhD
Dr. Mark Chang has over 20 years of experience as a statistician and, he is the founder of AGInception for Artificial General Intelligence Research. Previously, He served as Sr. Vice President, Strategic Statistical Consulting at Veristat, Vice President of Biometrics at AMAG Pharmaceuticals and, director and scientific fellow at Millennium/Takeda Pharmaceuticals. Dr. Chang is a fellow of the American Statistical Association and an adjunct professor of Biostatistics at Boston University. He is a co-founder of the International Society for Biopharmaceutical Statistics, co-chair of the Biotechnology Industry Organization (BIO) Adaptive Design Working Group, and a member of the Multiregional Clinical Trial (MRCT) Expert Group. He has published 11 books, including Artificial Intelligence for Drug Development, Precision Medicine and Healthcare, Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials, and many more.

Interested in joining our team?

Loading...